Trump tariff threat clouds final day of BRICS summit
US President Donald Trump's decision to hit "anti-American" BRICS nations -- including China and India -- with an extra 10 percent trade tariff roiled the final day of the bloc's summit in Rio de Janeiro Monday.
Trump threatened the 11-nation grouping -- which includes some of the world's fastest-emerging economies -- late on Sunday, after they warned against his "indiscriminate," damaging and illegal tariff hikes.
"Any Country aligning themselves with the Anti-American policies of BRICS, will be charged an ADDITIONAL 10% Tariff," Trump wrote on social media.
BRICS members account for about half the world's population and 40 percent of global economic output.
Members China, Russia and South Africa responded coolly to Trump's latest verbal barrage, insisting the bloc was not seeking confrontation with Washington.
But host Brazil's leftist President Luiz Inacio Lula da Silva was less diplomatic.
"We are sovereign nations," Lula said. "We don't want an emperor."
Conceived two decades ago as a forum for fast-growing economies, BRICS has come to be seen as a Chinese-driven effort to curb US global influence.
But it is a quickly expanding and often divergent grouping -- bringing together arch US foes like Iran and Russia, with some of Washington's closest allies in Latin America, the Middle East, Africa, and Asia.
Some US allies inside the bloc had tried to blunt criticism of Trump by not mentioning him or the United States by name in the summit statement.
Saudi Arabia -- one of the biggest purchasers of US high-tech weapons -- even kept its foreign minister away from Sunday's talks and a BRICS group photo, seemingly to avoid Washington's ire.
But such diplomatic gestures were lost on the US president who said "there will be no exceptions to this policy."
- No shows -
In April, Trump threatened a slew of punitive duties on dozens of economies, before backing off in the face of a fierce market sell-off.
Now he is threatening to impose unilateral levies on trading partners unless they reach "deals" by August 1, with BRICS nations seemingly faced with higher tariffs than planned.
It cannot have helped that BRICS leaders also condemned the recent US and Israeli bombing of Iran's nuclear facilities -- a show of solidarity with fellow member Iran.
Beijing on Monday insisted BRICS was not seeking confrontation with the United States.
"China has repeatedly stated its position that trade and tariff wars have no winners and protectionism offers no way forward," foreign ministry spokeswoman Mao Ning said.
Beijing also defended the bloc as "an important platform for cooperation between emerging markets and developing countries."
"It advocates openness, inclusivity, and win-win cooperation," Mao said.
"It does not engage in camp confrontation and is not targeted at any country," she added.
The Kremlin echoed that message with spokesman Dmitry Peskov telling Russian media that BRICS cooperation "has never been and will never be directed against third countries."
The political punch of this year's summit has been depleted by the absence of China's Xi Jinping, who skipped the meeting for the first time in his 12 years as president.
The Chinese leader is not the only notable absentee. Russian President Vladimir Putin, charged with war crimes in Ukraine, also opted to stay away, participating via video link.
He told counterparts that BRICS had become a key player in global governance.
arb/aks
Originally published as Trump tariff threat clouds final day of BRICS summit
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
23 minutes ago
- Sky News AU
Former CIA and FBI directors now under criminal investigation
Former CIA director John Brennan and former FBI director James Comey are under criminal investigation for their handling of the Trump-Russia probe. A Justice Department source revealed to Fox News that the pair are also being investigated for allegedly making false statements to Congress. FBI Director Kash Patel was referred to evidence of potential wrongdoing by Brennan from the current CIA Director John Ratcliffe, a DOJ source said. According to Fox News, a source revealed that an investigation into Brennan is underway, but further details were not given. It is currently unclear whether the investigation into the former CIA head goes beyond his alleged false statements to Congress. An investigation into the former FBI director Comey is underway, though sources could not divulge further information.
News.com.au
27 minutes ago
- News.com.au
‘Screw over': Truth about Donald Trump's plan to impose crippling 200 per cent tariffs on Australian pharmaceuticals
US President Donald Trump's plan to drop a 200 per cent tariff bomb on Australian pharmaceuticals is set to 'screw over' the sickest and most vulnerable in the United States suffering rare and life-threatening conditions including burns patients. As the Albanese Government scrambles to secure more information about the US government's latest plans, Australian officials are sounding the alarm given that pharmaceutical exports are worth over $2 billion a year. All plasma products collected in Australia stay here and are not exported to the US. Instead, the export issue relates to vaccines and blood products collected overseas and sent to Australia for processing before being returned to the US. President Donald Trump has threatened to introduce 200 per cent tariffs on pharmaceuticals – one of Australia's biggest exports to the US. Speaking to the media before a cabinet meeting, the President suggested the 'very, very high' levies on pharmaceuticals would not go into effect immediately, saying he would give drug manufacturers 'about a year, year and a half' to respond and relocate their operations to the US. 'They're going to be tariffs at a very high rate, like 200 per cent,' Mr Trump told reporters. 'We'll give them a certain period of time to get their act together,' he added, seemingly referring to drug manufacturers bringing back manufacturing into the US. Australia is subject to a 10 per cent 'baseline' tariff, which was the minimum rate imposed on all US trading partners by Mr Trump earlier this year. Australia's plasma exports to the US One of the biggest sections of the market includes blood products such as plasma products including exports linked to CSL Plasma which collects blood plasma in the United States. In 2023, Australia exported $1.42 billion of vaccines, blood, antisera, toxins and cultures, making it the 20th largest exporter of 208 in the world. Blood collection is a commercial operation in the United States, with plasma donors typically paid for their blood. CSL Plasma operates one of the world's largest and most sophisticated plasma collection networks, with nearly 350 plasma collection centers in the US and elsewhere. The blood products are mostly processed in the US but some are sent back to Australia to manufacture therapies for a variety of rare and life-threatening conditions. These conditions include primary immunodeficiencies, bleeding disorders like hemophilia, neurological disorders, and critical care needs like those arising from trauma or burns. One Australian official predicted that demand for the products would continue but the tariffs would 'screw over' patients relying on the notorious US healthcare system. Vulnerable patients will be hit with cost increases because the tariffs are paid by importers, not Australian exporters. CSL has a factory in Melbourne Biotech giant CSL has a plasma fractionation facility in Broadmeadows in Melbourne. The impact of the threatened tariffs relates to the commercial arm of CSL. which uses US blood products which are sourced in America and then processed in Australia before being sent back. 'Plasma manufacturing is a really fragile supply chain because it starts in a human vein,'' an industry source said. 'It's not a tap that you can turn on or off. You need people to vote with their feet to go into a facility that is enabled to collect plasma, and the demand for plasma products is growing globally each year.' 'Tariffs on pharmaceuticals impact the end user.' Treasurer Jim Chalmers 'very concerned' The Treasurer said on Wednesday that Washington's latest announcement was 'very concerning'. 'These are obviously very concerning developments,' Mr Chalmers told the ABC, adding that it had 'been a feature of recent months that we've had these sorts of announcements out of DC'. 'It's still early days. Obviously, we'll make a more detailed assessment of what's come out of the US in the usual way.' 'Our pharmaceuticals industry is much more exposed to the US market, and that's why we're seeking - urgently seeking - some more detail on what's been announced. 'But I want to make it really clear once again … our Pharmaceutical Benefit Scheme is not something that we're willing to trade away or do deals on – that won't change.' 'We've made it very clear that we think these tariffs are bad for the US, bad for Australia and bad for the global economy.' Mr Chalmers said one of the things the Albanese Government was 'most concerned' about was in addition to the direct impact on Australian workers and industries caused by this tariff, was the 'impact on global demand more broadly'. 'That's why we've been … at every opportunity, making the case that these tariffs are unjustified, they should be removed in line with our free trade agreement,' he said. The Prime Minister has described the taxes on Australian exports to the US as an 'act of economic self-harm'. 'Tariffs are a penalty on the country that is imposing them, because what they require is for goods to be purchased with a tax on top, and the US has made that decision,' the Prime Minister said. How plasma exports are used to help patients CSL Behring uses a process called plasma fractionation to separate the collected plasma into different components, such as immunoglobulins, coagulation factors, and other proteins. One example is helping people with bleeding disorders, with doctors utilising coagulation factors that are used to help patients with hemophilia and other bleeding disorders. Plasma-derived products are also used in emergency situations like severe trauma, burns, and shock to replace lost blood volume and proteins. For now, Australian officials concerned about the impact on blood product exports don't have full clarity on how it will impact the supply chain process.
Sky News AU
an hour ago
- Sky News AU
ASX 200 sinks as US President Donald Trump vows 50 per cent tariffs on copper, 200 per cent levies on pharmaceuticals
The ASX 200 is down on Wednesday as Donald Trump revealed he is considering 50 per cent tariffs on copper and eyes 200 per cent tariffs on pharmaceuticals in about a year's time. The index is down about 0.3 per cent after the first hour of trading with gold and copper company Evolution Mining sinking 7.9 per cent, Genesis Mineral shedding 5.8 per cent and copper miner Sandfire Resources slumping 5.2 per cent. Retirement village company Lifestyle Communities is down about 29 per cent after a court ruling found its lucrative exit fees were invalid. Investors are also watching Rio Tinto (up 0.4 per cent) and BHP (flat) which will face a hit from a copper mine they jointly run in Chile. Trump told reporters he is considering a raft of tariffs as the deadline for his 'Liberation Day' tariffs suspension looms. 'I believe the tariff on copper, we're going to make it 50 per cent,' Trump told reporters. He also plans to hit pharmaceuticals which could threaten major Australian companies such as the ASX's third largest company CSL. Medicinal and pharmaceutical products continue to be Australia's third largest export to the US behind gold and meat. 'They're going to be tariffed at a very, very high rate, like 200 per cent,' Trump said. 'We'll give them a certain period of time to get their act together.' Wall Street sank again on Tuesday with the Dow Jones falling 0.4 per cent, the S&P 500 sliding 0.1 per cent and the Nasdaq finishing flat. London's FTSE 250 jumped 0.2 per cent, Germany's DAX added 0.6 per cent and the STOXX Europe 600 rose 0.4 per cent. New Zealand's NZX 50 Index has shed 0.8 per cent while Japan's Nikkei 225 is flat.
